TRVI expands global trial sites to over 200 as it advances Phase III studies for non-IPF-ILD chronic cough treatment.
Trevi Therapeutics plans to align with the FDA in the second half of 2026 for its non-IPF-ILD chronic cough treatment, following the initiation of two Phase III trials. The company has outlined over 200 global trial sites to support the studies, including OCEAN-1, a 52-week trial for IPF-related chronic cough patients.
Management described 2026 as a critical execution year, building on prior trial phases and regulatory discussions. The expansion of trial sites aims to accelerate enrollment and data collection, positioning the company for potential market entry pending FDA review.
No immediate market reaction was disclosed in the earnings call insights.